Dianthus Therapeutics, Inc. /DE/ Operating Income
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported Operating Income of -$61.48 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-04
- Dianthus Therapeutics, Inc. /DE/ operating income (loss) for the quarter ending 2026-06-30 was -$61.48M.
- Dianthus Therapeutics, Inc. /DE/ operating income (loss) for the quarter ending 2026-03-31 was -$46.53M.
- Dianthus Therapeutics, Inc. /DE/ operating income (loss) for the quarter ending 2025-12-31 was -$69.54M.
- Dianthus Therapeutics, Inc. /DE/ operating income (loss) for the quarter ending 2025-09-30 was -$40.29M.
- Dianthus Therapeutics, Inc. /DE/ operating income (loss) for fiscal 2025 was -$177.93M.
- Dianthus Therapeutics, Inc. /DE/ operating income (loss) for fiscal 2024 was -$101.86M.
- Dianthus Therapeutics, Inc. /DE/ operating income (loss) for fiscal 2023 was -$48.17M.
- Dianthus Therapeutics, Inc. /DE/ operating income (loss) for fiscal 2022 was -$29.70M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$61.48M 10-Q · filed 2026-08-04 | -$108.02M 10-Q · filed 2026-08-04 | -$177.56M derived: sum of 3 quarters · filed 2026-08-04 | -$217.84M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | -$46.53M 10-Q · filed 2026-05-05 | -$116.07M derived: sum of 2 quarters · filed 2026-05-05 | -$156.36M derived: sum of 3 quarters · filed 2026-05-05 | -$191.29M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | -$69.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$109.83M derived: sum of 2 quarters · filed 2026-03-09 | -$144.76M derived: sum of 3 quarters · filed 2026-08-04 | -$177.93M 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | -$40.29M 10-Q · filed 2025-11-05 | -$75.22M derived: sum of 2 quarters · filed 2026-08-04 | -$108.39M 10-Q · filed 2025-11-05 | -$140.31M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | -$34.93M 10-Q · filed 2026-08-04 | -$68.10M 10-Q · filed 2026-08-04 | -$100.02M derived: sum of 3 quarters · filed 2026-08-04 | -$129.92M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | -$33.18M 10-Q · filed 2026-05-05 | -$65.09M derived: sum of 2 quarters · filed 2026-05-05 | -$94.99M derived: sum of 3 quarters · filed 2026-05-05 | -$117.20M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | -$31.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$61.82M derived: sum of 2 quarters · filed 2026-03-09 | -$84.02M derived: sum of 3 quarters · filed 2026-03-09 | -$101.86M 10-K · filed 2026-03-09 | ||||
| 2024-09-30 | -$29.90M 10-Q · filed 2025-11-05 | -$52.10M derived: sum of 2 quarters · filed 2025-11-05 | -$69.95M 10-Q · filed 2025-11-05 | -$82.90M derived: sum of 4 quarters · filed 2025-11-05 | ||||
| 2024-06-30 | -$22.20M 10-Q · filed 2025-08-07 | -$40.05M 10-Q · filed 2025-08-07 | -$53.00M derived: sum of 3 quarters · filed 2025-08-07 | -$68.76M derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | -$17.84M 10-Q · filed 2025-05-12 | -$30.80M derived: sum of 2 quarters · filed 2025-05-12 | -$46.56M derived: sum of 3 quarters · filed 2025-05-12 | -$58.34M derived: sum of 4 quarters · filed 2025-05-12 | ||||
| 2023-12-31 | -$12.96M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$28.71M derived: sum of 2 quarters · filed 2025-03-11 | -$40.49M derived: sum of 3 quarters · filed 2025-03-11 | -$48.17M 10-K · filed 2025-03-11 | ||||
| 2023-09-30 | -$15.76M 10-Q · filed 2024-11-07 | -$27.54M derived: sum of 2 quarters · filed 2024-11-07 | -$35.22M 10-Q · filed 2024-11-07 | -$45.91M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | -$11.78M 10-Q · filed 2024-08-08 | -$7.38M 10-Q · filed 2023-08-03 | -$19.46M 10-Q · filed 2024-08-08 | -$39.51M 10-Q · filed 2023-08-03 | -$30.15M derived: sum of 3 quarters · filed 2024-08-08 | -$38.41M derived: sum of 4 quarters · filed 2024-08-08 | ||
| 2023-03-31 | -$7.68M 10-Q · filed 2024-05-09 | -$32.13M 10-Q · filed 2023-05-15 | -$18.38M derived: sum of 2 quarters · filed 2024-05-09 | -$26.63M derived: sum of 3 quarters · filed 2024-05-09 | -$44.71M derived: sum of 4 quarters · filed 2024-05-09 | |||
| 2022-12-31 | -$10.69M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$18.95M derived: sum of 2 quarters · filed 2024-03-21 | -$37.03M derived: sum of 3 quarters · filed 2024-03-21 | -$29.70M 10-K · filed 2024-03-21 | -$80.90M 10-K · filed 2023-03-23 | |||
| 2022-09-30 | -$8.25M 10-Q · filed 2023-11-09 | -$17.25M 10-Q · filed 2022-11-03 | -$26.34M derived: sum of 2 quarters · filed 2023-11-09 | -$19.01M 10-Q · filed 2023-11-09 | -$59.17M 10-Q · filed 2022-11-03 | -$8.71M derived: sum of 4 quarters · filed 2023-12-21 | ||
| 2022-06-30 | -$18.08M 10-Q · filed 2023-08-03 | -$41.92M 10-Q · filed 2023-08-03 | -$451.00K derived: sum of 3 quarters · filed 2023-12-21 | -$18.70M derived: sum of 4 quarters · filed 2023-12-21 | ||||
| 2022-03-31 | -$23.83M 10-Q · filed 2023-05-15 | $17.63M derived: sum of 2 quarters · filed 2023-12-21 | -$613.00K derived: sum of 3 quarters · filed 2023-12-21 | -$18.22M derived: sum of 4 quarters · filed 2023-12-21 | ||||
| 2021-12-31 | $41.47M derived: 8-K 12 month − 10-Q 9 month · filed 2023-12-21 | $23.22M derived: sum of 2 quarters · filed 2023-12-21 | $5.61M derived: sum of 3 quarters · filed 2023-12-21 | -$13.09M 8-K · filed 2023-12-21 | -$74.69M 10-K · filed 2022-03-08 | |||
| 2021-09-30 | -$18.25M 10-Q · filed 2022-11-03 | -$35.85M derived: sum of 2 quarters · filed 2022-11-03 | -$54.55M 10-Q · filed 2022-11-03 | -$73.62M derived: sum of 4 quarters · filed 2022-11-03 | ||||
| 2021-06-30 | -$17.61M 10-Q · filed 2022-08-04 | -$36.31M 10-Q · filed 2022-08-04 | -$55.37M derived: sum of 3 quarters · filed 2022-08-04 | -$73.75M derived: sum of 4 quarters · filed 2022-08-04 | ||||
| 2021-03-31 | -$18.70M 10-Q · filed 2022-05-16 | -$37.76M derived: sum of 2 quarters · filed 2022-05-16 | -$56.14M derived: sum of 3 quarters · filed 2022-05-16 | -$76.16M derived: sum of 4 quarters · filed 2022-05-16 | ||||
| 2020-12-31 | -$19.07M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | -$37.45M derived: sum of 2 quarters · filed 2022-03-08 | -$57.46M derived: sum of 3 quarters · filed 2022-03-08 | -$78.70M 10-K · filed 2022-03-08 | ||||
| 2020-09-30 | -$18.38M 10-Q · filed 2021-11-04 | -$38.39M derived: sum of 2 quarters · filed 2021-11-04 | -$59.64M 10-Q · filed 2021-11-04 | -$84.27M derived: sum of 4 quarters · filed 2021-11-04 | ||||
| 2020-06-30 | -$20.01M 10-Q · filed 2021-08-05 | -$41.26M 10-Q · filed 2021-08-05 | -$65.89M derived: sum of 3 quarters · filed 2021-08-05 | -$88.54M derived: sum of 4 quarters · filed 2021-08-05 | ||||
| 2020-03-31 | -$21.24M 10-Q · filed 2021-05-06 | -$45.88M derived: sum of 2 quarters · filed 2021-05-06 | -$68.53M derived: sum of 3 quarters · filed 2021-05-06 | -$87.86M derived: sum of 4 quarters · filed 2021-05-06 | ||||
| 2019-12-31 | -$24.64M 10-K · filed 2020-03-03 | -$47.28M derived: sum of 2 quarters · filed 2020-11-05 | -$66.62M derived: sum of 3 quarters · filed 2020-11-05 | -$82.97M 10-K · filed 2021-03-03 | ||||
| 2019-09-30 | -$22.64M 10-Q · filed 2020-11-05 | -$41.98M derived: sum of 2 quarters · filed 2020-11-05 | -$58.33M 10-Q · filed 2020-11-05 | -$76.26M derived: sum of 4 quarters · filed 2020-11-05 | ||||
| 2019-06-30 | -$19.34M 10-Q · filed 2020-08-06 | -$35.69M 10-Q · filed 2020-08-06 | -$53.62M derived: sum of 3 quarters · filed 2020-08-06 | -$70.32M derived: sum of 4 quarters · filed 2020-08-06 | ||||
| 2019-03-31 | -$16.35M 10-Q · filed 2020-05-07 | -$34.28M derived: sum of 2 quarters · filed 2020-05-07 | -$50.98M derived: sum of 3 quarters · filed 2020-05-07 | -$65.01M derived: sum of 4 quarters · filed 2020-05-07 | ||||
| 2018-12-31 | -$17.93M 10-K · filed 2020-03-03 | -$34.63M derived: sum of 2 quarters · filed 2020-03-03 | -$48.66M derived: sum of 3 quarters · filed 2020-03-03 | -$59.96M 10-K · filed 2020-03-03 | ||||
| 2018-09-30 | -$16.70M 10-K · filed 2020-03-03 | -$30.73M derived: sum of 2 quarters · filed 2020-03-03 | -$42.03M 10-Q · filed 2019-11-13 | -$50.20M derived: sum of 4 quarters · filed 2020-03-03 | ||||
| 2018-06-30 | -$14.03M 10-K · filed 2020-03-03 | -$25.33M 10-Q · filed 2019-08-08 | -$33.50M derived: sum of 3 quarters · filed 2020-03-03 | -$40.52M derived: sum of 4 quarters · filed 2020-03-03 | ||||
| 2018-03-31 | -$11.31M 10-K · filed 2020-03-03 | -$19.48M derived: sum of 2 quarters · filed 2020-03-03 | -$26.49M derived: sum of 3 quarters · filed 2020-03-03 | -$42.22M derived: sum of 4 quarters · filed 2020-03-03 | ||||
| 2017-12-31 | -$8.17M 10-K · filed 2019-03-19 | -$15.19M derived: sum of 2 quarters · filed 2019-03-19 | -$30.92M derived: sum of 3 quarters · filed 2019-03-19 | -$35.73M 10-K · filed 2020-03-03 | ||||
| 2017-09-30 | -$7.01M 10-K · filed 2019-03-19 | -$22.75M derived: sum of 2 quarters · filed 2019-03-19 | -$27.56M 10-Q · filed 2018-11-08 | |||||
| 2017-06-30 | -$15.73M 10-K · filed 2019-03-19 | -$20.54M 10-Q · filed 2018-08-09 | ||||||
| 2017-03-31 | -$4.81M 10-K · filed 2019-03-19 | |||||||
| 2016-12-31 | -$9.27M 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |